drugset / Trial / NCT06989671
SYS6002 Plus JMT101 and Enlonstobart Injection in Participants With HNSCC
RandomizedFactorialOpen-labelTreatment
Summary
This is a Phase II study of anti-nectin-4 ADC combined with the EGFR monoclonal antibody and the PD-1 monoclonal antibody in participants with advanced head and neck squamous cell carcinoma.
Timeline
- Start
- 2025-08-30
- Primary completion
- 2027-12-30
- Completion
- 2028-07-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | BECOTATUG | Monoclonal antibody | — | Intravenous |
| Subject | Enlonstobart | Monoclonal antibody | — | Intravenous |
| Subject | SYS6002 | Other / unclassified | — | Intravenous |